Search clinical trials for: Pharmacokinetic analysis

Total 6568 results

University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Children's Cancer and Leukaemia Group

Unknown

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Nonneoplastic Condition

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Suspended

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
University of Southern California
National Cancer Institute (NCI); Oncolytics Biotech

Completed

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; Whittier Foundation

Terminated

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain Only

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Immunodeficiency Syndrome | Non-Cancer Diagnosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Childhood Acute Lymphoblastic Leukemia | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Prolymphocytic Leukemia | Refractory Chronic... and other conditions

United States, Denmark
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial Tumor

United States
National Cancer Institute (NCI)

Terminated

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Amyloidosis | Immunoglobulin Light Chain Deposition
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
University of Arkansas
Celgene Corporation

Completed

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Metastatic Osteosarcoma

United States
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Malignant Solid Neoplasm | Colitis | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
University of Washington

Active, not recruiting

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Donor | Hematopoietic Cell Transplant Recipient | HLA-A*0201 Positive Cells Present

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Childhood Acute Lymphoblastic Leukemia in Remission

United States, Canada, Australia
University of Washington
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Crohn's Allogeneic Transplant Study (CATS)

Crohn Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States

Search clinical trials for: Pharmacokinetic analysis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations